Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended			6 Months Ended
		Jun. 30, 2018		Jul. 01, 2017	Jun. 30, 2018		Jul. 01, 2017
Disaggregation of Revenue [Line Items]
Net sales		$ 1,186.4	[1]	$ 1,237.9	$ 2,403.4	[1]	$ 2,431.9
CHCA
Disaggregation of Revenue [Line Items]
Net sales		596.8		604.9	1,198.4		1,187.6
CHCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[2]	109.3			250.8
CHCA | Infant Nutritionals
Disaggregation of Revenue [Line Items]
Net sales		109.2			212.6
CHCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[2]	103.0			195.2
CHCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[2]	92.2			185.9
CHCA | Smoking Cessation
Disaggregation of Revenue [Line Items]
Net sales		71.2			137.1
CHCA | Animal Health
Disaggregation of Revenue [Line Items]
Net sales		31.9			58.2
CHCA | Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	4.3			7.3
CHCA | Other CHCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	75.7			151.3
CHCI
Disaggregation of Revenue [Line Items]
Net sales		381.0		376.5	782.4		751.5
CHCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		86.1			175.8
CHCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales		84.7			183.4
CHCI | Personal Care and Derma-Therapeutics
Disaggregation of Revenue [Line Items]
Net sales		79.7			155.3
CHCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		30.4			58.5
CHCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales		27.9			61.1
CHCI | Other CHCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	72.2			148.3
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 208.6		$ 240.4	$ 422.6		$ 457.8

[1] The net sales by geography is derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.